Molecular InformaticsBioinformaticsPeer-reviewed journal article
Deep Modeling of Gain of Function Mutations on Androgen Receptor
Jiaying YouiD, Jane Foo, Nada LallousiD, Artem R CherkasoviD
Abstract
The efficiency of Androgen Receptor (AR) pathway inhibitors for prostate cancer (PCa) is on decline due to resistance mechanisms including the occurrence of gain-of-function mutations on human androgen receptor (AR). Hence, understanding and predicting such mutations is crucial for developing effective PCa treatment strategies. Leveraging accumulated data on clinically relevant AR mutants with recent advances in deep modeling techniques, this study aims to unveil and quantify critical AR mutation-drug relationships. By incorporating molecular descriptors for drugs and mutated genes sequences, this work represented these features as single vectors and demonstrates their effectiveness in modeling AR mutant responses to conventional antiandrogens. The developed approach achieves up to 80% accuracy in predicting the gain-of-function behavior of AR mutants and therefore can potentially uncover unknown agonist/antagonist relationships among mutant-drug pairs.
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 8th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Deep Learning Modelling of Androgen Receptor Responses to Prostate Cancer Therapies
O. Snow, N. Lallous, … A. Cherkasov·bioRxiv·Jan 15, 2020
- 5β-Dihydrotestosterone reveals a mutant androgen receptor vulnerability in prostate cancer
Samual Adams, Lindsey Phelan, … Jianneng Li·bioRxiv·Jul 15, 2026
- Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.
Giuditta Illuzzi, Alessandro Galbiati, … Mark J. O’Connor·NAR CancerPeer-reviewed·Oct 7, 2025
- Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer.
Haleema Azam, Colin Veale, … Maria Prencipe·PLoS ONEPeer-reviewed·Dec 13, 2024
- TRIM24 Degradation Counteracts Adaptation to Androgen Receptor Inhibition in Prostate Cancer
Daniela Bossi, Arianna Vallerga, … Jean-Philippe Paul. Theurillat·bioRxiv·Aug 21, 2025
- GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance
C. L. Sawyers, E. Lee, … A. Gopalan·bioRxiv·Oct 2, 2018